# Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

> **NCT01316692** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IIIc Melanoma
- Stage IV Melanoma

## Interventions

- **OTHER:** laboratory biomarker identification and analysis
- **PROCEDURE:** biopsy
- **OTHER:** immunohistochemistry/tissue microarrays
- **GENETIC:** TdT-mediated dUTP nick end labeling assay
- **OTHER:** mass spectrometry

## Key facts

- **NCT ID:** NCT01316692
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2014-11
- **Final completion:** 2015-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2016-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316692, "Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01316692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*